

## Julie A. Oliver

<http://www4.uwm.edu/letscli/biologicalsciences/facultystaff/oliver/index.cfm>

Department of Biological Sciences  
University of Wisconsin-Milwaukee  
Room N209 Lapham Hall  
3209 North Maryland Avenue  
Milwaukee, WI 53211 USA

Office 414-229-4317  
Department Fax 414-229-3926  
Email [joliver@uwm.edu](mailto:joliver@uwm.edu)

### Education

1994 – 1999 Postdoctoral research with Maureane Hoffman, Dougald M. Monroe, and Harold R. Roberts at the Center for Thrombosis and Hemostasis, University of North Carolina-Chapel Hill

1992 – 1994 Postdoctoral research with Peter J. Newman at the Blood Research Institute of the Blood Center of Wisconsin, Milwaukee, WI

1982 – 1992 MS and PhD research with Ralph M. Albrecht in the Department of Pharmacology, University of Wisconsin-Madison School of Pharmacy. Thesis title: “The Relationship of Platelet Morphology, Aggregation, and Secretion.”

1978 – 1982 Bachelor of Science in Zoology and Psychology with minor in Chemistry, University of Wisconsin-Eau Claire. Graduated Magna Cum Laude.

### Appointments and Employment

2013 – present Associate Professor, Department of Biological Sciences, University of Wisconsin-Milwaukee

2006 – 2013 Assistant Professor, Department of Biological Sciences, University of Wisconsin-Milwaukee

2007 – present Assistant Professor L/I, Department of Animal Sciences, University of Wisconsin-Madison (courtesy appointment)

2004 – 2006 Assistant Scientist in laboratory of Ralph M. Albrecht, Department of Animal Sciences, University of Wisconsin-Madison

2003 – 2005 Instructor, Department of Biological Sciences, University of Wisconsin-Milwaukee

2001 – 2003 Research Associate in laboratory of Thomas F. Tedder, Department of Immunology, Duke University Medical Center, Durham, NC

1999 – 2000	Scientist, Research Division, Pharmanetics, Inc., Raleigh, NC
1994 – 1999	Postdoctoral Fellow, University of North Carolina-Chapel Hill
1992 – 1994	Postdoctoral Fellow, Blood Center of Wisconsin
1985 – 1992	Research Assistant, University of Wisconsin-Madison
1982 – 1984	Teaching Assistant, University of Wisconsin-Madison School of Pharmacy

### Awards and Honors

2010	<i>Microscopy and Microanalysis</i> Best Instrumentation, Software, or Protocol Development Paper of 2010
2010	UW-Milwaukee Graduate School Research Fellow
2009	Finalist, Shaw Scientist Competition, Greater Milwaukee Foundation
1996, 97, 99	Travel Award, American Society of Hematology Annual Meeting
1982	Outstanding Senior Award, University of Wisconsin-Eau Claire
1979 - 1982	Beta Beta Beta, Biology Honor Society, UW-Eau Claire
1979 - 1982	Psi Chi, Psychology Honor Society, UW-Eau Claire
1978	Alpha Lambda Delta, Freshman Women's Honor Society, UW-Eau Claire

### Publications

#### Submitted / Under Revision:

Pisterzi, LF, MR Stoneman, F Huang, AP Sullivan, **JA Oliver**, JW Wells, V Raicu. Oligomeric size and configuration of G protein-coupled receptors in living cells, under revision, Nat. Commun., 2012.

#### Published:

Krystofiak, ES\*, EC Mattson\*, PM Voyles, CJ Hirschmugl, RM Albrecht, M Gajdardziska-Josifovska, **JA Oliver**. 2013. Multiple morphologies of gold-magnetite heterostructure nanoparticles are effectively functionalized with protein for cell targeting, Microsc. Microanal., 19:821-834. \*Authors contributed equally to this work.

Patowary, S\*, E Alvarez-Curto\*, T-R Xu, JD Holtz, **JA Oliver**, G Milligan, V Raicu. 2013. The muscarinic M<sub>3</sub> acetylcholine receptor exists as two differently sized complexes at the plasma membrane, Biochem. J., 452:303-312. \*Authors contributed equally to this work.

Singh DR, MM Mohammad, S Patowary, **JA Oliver**, L Movileanu, V Raicu. 2013. Determination of the quaternary structure of a bacterial ABC transporter in living cells, Integr. Biol., 5:312-323.

Krystofiak, ES\*, VZ Matson\*, DA Steeber, **JA Oliver**. 2012. Elimination of tumor cells using folate receptor targeting by antibody-conjugated, gold-coated magnetite nanoparticles in a murine breast cancer model, *J. Nanomater.*, 2012:431012, Focus Issue "Nanostructures for Medicine and Pharmaceuticals 2012." \*Authors contributed equally to this work.

Stoneman, MR, S Patowary, DR Singh, L Komarova, LG Westrick, **JA Oliver\***, V Raicu\*. 2012. Quantifying the efficiency of various FRET constructs using OptiMiS™, *Biotechniques*, 52:191-195. \*Co-corresponding authors.

Stoneman, MR, S Patowary, MT Roesch, DR Singh, V Strogolov, **JA Oliver**, V Raicu. 2011. Determination of the stoichiometry, structure, and distribution in living cells of protein complexes from analysis of single-molecular-complexes FRET, *Proc. SPIE* 7903-73, DOI: 10.1117/12.875249.

Meyer, DA, **JA Oliver**, RM Albrecht. 2010. Colloidal palladium particles of different shapes for electron microscopy labeling, *Microsc. Microanal.*, 16:33-42. **Winner of Microscopy & Microanalysis Best Instrumentation, Protocol or Software Development Paper of 2010.**

Murugesan, R, E Hanley, RM Albrecht, **JA Oliver**, JA Heintz, JL Lauer, JL Shohet. 2008. The effects of plasma-processing conditions on the morphology of adherent human blood platelets, *J. Appl. Phys.*, 103(9):093302-1 – 093302-5.

Uchida, J, Y Hamaguchi, **JA Oliver**, JV Ravetch, JC Poe, KM Haas, and TF Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy, *J. Exp. Med.*, 199:1659-1669.

Haas, KM, FR Toapanta, **JA Oliver**, JC Poe, JH Weis, DR Karp, JF Bower, TM Ross, and TF Tedder. 2004. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression, *J. Immunol.*, 172:5833-5837.

Allen, GA, AS Wolberg, **JA Oliver**, M Hoffman, HR Roberts, and DM Monroe. 2004. Impact of procoagulant concentration on rate, peak, and total thrombin generation in a model system, *J. Thromb. Haemost.*, 2:402-413.

Uchida, J, Y Lee, M Hasegawa, Y Liang, A Bradney, **JA Oliver**, K Bowen, DA Steeber, KM Haas, JC Poe, and TF Tedder. 2004. Mouse CD20 expression and function, *Int. Immunol.*, 16:119-129.

**Oliver, JA**, DM Monroe, FC Church, H. Roberts, and M Hoffman. 2002. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces, *Blood*, 100:539-546.

**Oliver, JA**, DM Monroe, HR Roberts, and M Hoffman. 1999. Thrombin activates factor XI on activated platelets in the absence of factor XII, *Arterioscler. Thromb. Vasc. Biol.*, 19:170-177.

Chang, J-Y, DM Monroe, **JA Oliver**, and HR Roberts. 1999. TFPIβ, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene, *Thromb. Haemost.*, 81:45-49.

Thomas, DW, RB Mannon, PJ Mannon, A Latour, **JA Oliver**, M Hoffman, O Smithies, BH Koller, and TM Coffman. 1998. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A<sub>2</sub>, *J. Clin. Invest.*, 102:1994-2001.

Monroe, DM, M Hoffman, **JA Oliver**, and HR Roberts. 1998. A possible mechanism of action of activated factor VII independent of tissue factor, *Blood Coag. Fibrinol.*, 9 (suppl 1):S15-S20.

Kjalke, M, DM Monroe, M Hoffman, **JA Oliver**, M Ezban, U Hedner, and HR Roberts. 1998. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation, *Blood Coag. Fibrinol.*, 9 (suppl 1):S21-S25.

Kjalke M, DM Monroe, M Hoffman, **JA Oliver**, M Ezban, and HR Roberts. 1998. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation, *Thromb. Haemost.*, 80:578-584.

Chang, J-Y, DM Monroe, **JA Oliver**, DK Liles, and HR Roberts. 1998. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI), *Thromb. Haemost.*, 79:306-309.

Roberts, HR, DM Monroe, **JA Oliver**, J-Y Chang, and M Hoffman. 1998. Newer concepts of blood coagulation, *Haemophilia*, 4:331-334.

Monroe, DM, M Hoffman, **JA Oliver**, and HR Roberts. 1997. Platelet activity of high-dose factor VIIa is independent of tissue factor, *Br. J. Haematol.*, 99:542-547.

Kjalke, M, **JA Oliver**, DM Monroe, M Hoffman, M Ezban, U Hedner, and HR Roberts. 1997. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration, *Thromb. Haemost.*, 78:1202-1208.

Hudetz AG, **JA Oliver**, JD Wood, PJ Newman, and JP Kampine. 1997. Leukocyte adhesion in pial cerebral venules after PMA stimulation and ischemia/reperfusion in vivo, *Adv. Exp. Med. Biol.*, 411:513-518.

Hoffman, M, DM Monroe, **JA Oliver**, and HR Roberts. 1995. Factor IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation, *Blood*, 86:1794-1801.

Goldberger, A, KA Middleton, **JA Oliver**, C Paddock, H-C Yan, HM DeLisser, SM Albelda, and PJ Newman. 1994. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form, *J. Biol. Chem.*, 269:17183-17189.

**Oliver, JA** and RM Albrecht. 1987. Colloidal gold labelling of fibrinogen receptors in epinephrine- and ADP-activated platelet suspensions, *Scanning Microsc.*, 1:745-756.

**Invited Book Chapters:**

Albrecht, RM and **Oliver JA**. 2011. Labeling considerations for confocal microscopy, Chapter 5 in *Basic Confocal Microscopy*, R Price and J Jerome (eds.), 1<sup>st</sup> edition, Springer, New York, pp. 79-114.

**Oliver, JA** and RM Albrecht. 1988. Colloidal gold labelling of fibrinogen receptors in epinephrine- and ADP-activated platelet suspensions, in *Colloidal Gold Labelling: Biotechnology and Bioapplications*, RM Albrecht, GM Hodges and O Johari (eds.), Scanning Microscopy International, Chicago, pp. 113-124.

Albrecht, RM, **JA Oliver**, and JC Loftus. 1985. Observation of colloidal gold labelled platelet surface receptors and the underlying cytoskeleton, in *The Science of Biological Specimen Preparation*, M Mueller, RP Becker, A Boyde and JJ Wolosewick (eds.), SEM, Inc., Chicago, pp. 185-193.

**Peer-reviewed Proceedings and Abstracts:**

Krystofiak, ES, EC Mattson, RM Albrecht, M Gajdardziska-Josifovska, **JA Oliver**. 2013. Multiple morphologies of gold-coated magnetite nanoparticles are conjugated with ligands and can produce receptor-mediated biological effects, *Microsc. Microanal.*, 19 (Suppl 2), in press.

Mohammad MM, DR Singh, S Patowary, **JA Oliver**, L Movileanu, V Raicu. 2012. FRET-based method to decipher the stoichiometry and structural assembly of bacterial ABC transporter involved in exporting endotoxins, *Mol. Biol. Cell*, Supplement, Abstract 627.

Krystofiak, ES, EC Mattson, M Gajdardziska-Josifovska, **JA Oliver**. 2012. Protein conjugation by non-ionic adsorption both functionalizes and stabilizes gold-coated magnetite nanoparticles, *Microsc. Microanal.*, 18 (Suppl 2):1650-1651. **Recipient of Microscopy Society of America Presidential Student Award for 2012**, as judged on scientific content, quality of figures, and readability. Award provided meeting registration, travel, and hotel accommodations to the presenting student author (Mr. Krystofiak).

Mattson, EC, ES Krystofiak, PM Voyles, M Gajdardziska-Josifovska, **JA Oliver**. 2012. Understanding gold growth on magnetite nanoparticles using scanning transmission electron microscopy, *Microsc. Microanal.*, 18 (Suppl 2):358-359.

Patowary, S, E Alvarez-Curto, T-R Xu, **JA Oliver**, G Milligan, V Raicu. 2012. Quaternary structure determination of the  $M_3$  muscarinic acetylcholine receptors based on spectral-FRET, *Biophys. J.*, 102:522a.

Singh, DR, MM Mohammad, KR Howard, **JA Oliver**, L Movileanu, V Raicu. 2012. Quaternary structure of the NBD subunit Wzt of a bacterial ABC transporter in the absence and presence of TMD subunit Wzm using pixel-level FRET, *Biophys. J.*, 102:659a.

Albrecht, RM, O Olorundare, **JA Oliver**, DA Meyer. 2011. Nanoparticle labels for co-localization and correlative imaging at high spatial resolution, *Microsc. Microanal.*, 17 (Suppl 2):358-359.

Mattson, EC, ES Krystofiak, PM Voyles, CJ Hirschmugl, M Gajdardziska-Josifovska, **JA Oliver**. 2011. Synthesis, structure, and morphology of magnetic core-shell nanoparticles, *Microsc. Microanal.*, 17 (Suppl 2):1428-1429. “**Best Physical Sciences Poster of the Day**” award, chosen by the MSA Awards Committee on-site. Award provided a cash prize to the presenting author (Mr. Mattson).

**Oliver, JA**, ES Krystofiak, LG Westrick. 2011. Fibrinogen binding to activated platelets in the presence of plasma concentration of the natural ligand may be sufficient to allow therapeutic targeting, *J. Thromb. Haemost.*, 9 (Suppl 2):P-TH-038. “**Best of Posters**” award, based on competitive scores of abstracts.

**Oliver, JA**, ES Krystofiak. 2011. Destruction of activated platelets with fibrinogen-conjugated core-shell nanoparticles, *J. Thromb. Haemost.*, 9 (Suppl 2):P-TH-040. “**Best of Posters**” award, based on competitive scores of abstracts.

Singh, DR, MM Mohammad, KR Howard, **JA Oliver**, L Movileanu, V Raicu. 2011. Localization, interaction, and stoichiometry of the wzm and wzt subunits of a bacterial ABC transporter using spectrally resolved FRET, presented at “FRET at 65: A Celebration of Förster,” March 10, 2011, University of Virginia, Charlottesville, VA.

Patowary, S, LF Pisterzi, MR Stoneman, V Strogolov, JW Wells, **JA Oliver**, V Raicu. 2011. Experimental testing of the FRET theory for multimeric complexes using reference fluorescence standards, presented at “FRET at 65: A Celebration of Förster,” March 10, 2011, University of Virginia, Charlottesville, VA.

Pisterzi, LF, MR Stoneman, F Huang, **JA Oliver**, JW Wells, V Raicu. 2011. Oligomeric structure of muscarinic and adrenergic receptors in live cells, *Biophys. J.*, 100:277a.

Mohammad, MM, DR Singh, KR Howard, **JA Oliver**, V Raicu, L Movileanu. 2011. Deciphering the subunit stoichiometry and structural assembly of bacterial ABC transporter, *Biophys. J.*, 100:8a.

Patowary, S, LF Pisterzi, MR Stoneman, V Strogolov, **JA Oliver**, JW Wells, V Raicu. 2011. Accurate FRET measurements and testing of the theory for multimeric complexes using reference fluorescence standards, *Biophys. J.*, 100:140a.

Westrick, LG, ES Krystofiak, **JA Oliver**. 2010. Extensive reserve capacity for the binding and movement of fibrinogen on the surface of activated human platelets, *Circulation*, 122 (21 Suppl):A13212.

Krystofiak, ES, S Rajput, RM Albrecht, M Gajdardziska-Josifovska, **JA Oliver**. 2010. Synthesis and characterization of magnetite-gold core-shell nanoparticles, *Microsc. Microanal.*, 16 (Suppl 2):1714-1715.

Krystofiak, ES, **JA Oliver**. 2009. Human fibrinogen supports normal hemostatic function in a murine platelet system. *J. Thromb. Haemost.*, 7 (Suppl 2):PP-MO-039.

Strogolov, V, LG Westrick, **JA Oliver**. 2009. Detecting tissue factor-positive cells in a mixed population by scanning electron microscopy, *J. Thromb. Haemost.*, 7 (Suppl 2):PP-WE-122.

Meyer, DA, R Bleher, IK Kandela, **JA Oliver**, RM Albrecht. 2006. The development of alternative markers for transmission electron microscopy and correlative transmission electron and light microscopy, *Microsc. Microanal.*, 12 (Suppl 2):32-33.

Meyer, DA, **JA Oliver**, RM Albrecht. 2005. A method for the quadruple labeling of platelet surface epitopes for transmission electron microscopy, *Microsc. Microanal.*, 11 (Suppl 2):142-143.

Karp, DR, KM Haas, FR Toapanta, **JA Oliver**, JC Poe, JH Weiss, JE Bower, TM Ross, TF Tedder. 2004. C3d functions as a molecular adjuvant in the absence of complement receptor 2, *Mol. Immunol.*, 41:254.

Uchida, J, **JA Oliver**, JC Poe, KM Haas, DA Steeber, TF Tedder. 2003. Mouse CD20 as a model target for immunotherapy requires Fe receptor-dependent cell-mediated effector functions that are independent of complement-mediated cytotoxicity, *FASEB J*, 17 (Supplement):C331.

Mize, PD, G Cutsforth, **JA Oliver**, D Mahan, and A DeAnglis. 2001. Development of the Rapidpoint™ Coag enoxaparin test card system to monitor Lovenox® (enoxaparin sodium) in PCI patients, *Blood*, 98(11):46a.

Mize, PD, G Cutsforth, **JA Oliver**, D Mahan, and A DeAnglis. 2001. Rapidpoint™ Coag enoxaparin test: clinical results for a POC method for monitoring Lovenox® (enoxaparin sodium) in patients undergoing PCI, *Blood*, 98(11):48a.

**Oliver, JA**, DM Monroe, HR Roberts, FC Church, and M Hoffman. 1999. Activated protein C (APC) functions by inhibiting initiation of coagulation rather than by terminating a hemostatic response, *Blood*, 94 (Suppl 1):224a.

Wolberg, AS, **JA Oliver**, PA McDowell, LL Phillips, ME Mohan, DM Monroe, HR Roberts, and M Hoffman. 1999. The initial rate, but not the total amount, of thrombin (IIa) generated determines fibrin clot structure in a cell-based model of coagulation, *Blood*, 94 (Suppl 1):230a.

**Oliver, JA**, DM Monroe, HR Roberts, FC Church, and M Hoffman. 1999. Activated protein C cleaves factor Va more efficiently on endothelium than on platelets, *Thromb. Haemost.*, (Supplement):425.

Allen, GA, AS Wolberg, **JA Oliver**, M Hoffman, HR Roberts, and DM Monroe. 1999. Effect of varied procoagulant concentration on thrombin generation in a model system, *Thromb. Haemost.*, (Supplement):316-317.

Kon, RH, AS Wolberg, **JA Oliver**, DM Monroe, and M Hoffman. 1999. Factor XI is a contaminant in intravenous immunoglobulin (IVIG) preparations, *Thromb. Haemost.*, (Supplement):459-460.

**Oliver, JA**, DM Monroe, HR Roberts, M Hoffman. 1998. Activated protein C acts on the endothelium, not the platelet surface, in a cell-based model of coagulation, July, 1998 Gordon Research Conference on Hemostasis, Plymouth State College, Plymouth, NH.

**Oliver, JA**, DM Monroe, HR Roberts, and M Hoffman. 1997. Activated platelets provide a surface for the activation of factor XI by thrombin and factor Xa, *Blood*, 90:28a.

Chang, J-Y, DM Monroe, **JA Oliver**, and HR Roberts. 1997. TFPI $\beta$ , a second product from the human tissue factor pathway inhibitor (TFPI) gene by alternatively splicing, *Blood*, 90:294a.

Kjalke, M, DM Monroe, M Hoffman, **JA Oliver**, M Ezban, and HR Roberts. 1997. Comparison of the effects of active site-inhibited factors VIIa, Xa, and IXa in a cell-based model for tissue factor-initiated coagulation, *Thromb. Haemost.*, Suppl:11.

Kjalke, M, **JA Oliver**, DM Monroe, M Hoffman, M Ezban, U Hedner, and HR Roberts. 1997. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin treatment, *Thromb. Haemost.*, Suppl:12.

Monroe, DM, M Hoffman, **JA Oliver**, and HR Roberts. 1997. High dose factor VIIa activates factor X on activated platelets in the absence of tissue factor, *Thromb. Haemost.*, Suppl:168.

**Oliver, JA**, DM Monroe, M Hoffman, and HR Roberts. 1996. Factor XI increases thrombin generation in a cell-based system in the absence of factor XII, *Blood*, 88 (Suppl 1):469a.

Kjalke, M, **JA Oliver**, DM Monroe, M Hoffman, M Ezban, HR Roberts, and U Hedner. 1996. The effect of active site-inhibited coagulation factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin treatment, *Blood*, 88 (Suppl 1):67b.

Kjalke, M, DM Monroe, M Hoffman, **JA Oliver**, M Ezban, U Hedner, HR Roberts. 1997. The effects of factor VIIa in a cell-based model for tissue factor-initiated coagulation, September, 1997 4th Symposium on New Aspects of Haemophilia Treatment, Copenhagen, Denmark.

**Oliver, JA**, DM Monroe, HR Roberts, M Hoffman. 1997. Factor XI increases thrombin generation in a cell-based system in the absence of factor XII, April, 1997 1st Annual Duke University Medical Center Department of Pathology Research Retreat, Durham, NC.

Kjalke, M **JA Oliver**, M Hoffman, DM Monroe, M Ezban, U Hedner, HR Roberts. 1996. Active site-inhibited factor VIIa blocks platelet activation, thrombin generation and accumulation of platelet bound factor X in a tissue factor-initiated system, June, 1996 Gordon Research Conference on Hemostasis, Proctor Academy, Andover, NH.

**Oliver, JA**, DM Monroe, K Gaud, HR Roberts, and M Hoffman. 1995. Coagulation factor XIa enhances the binding of both zymogen and activated factor IX to stimulated human platelets, *Blood*, 86 (Suppl 1):450a.

**Oliver, JA**, M Hoffman, DM Monroe, M Ezban, U Hedner, and HR Roberts. 1995. Active site-inhibited coagulation factor VIIa blocks platelet activation, thrombin generation, and accumulation of platelet-bound factor X in a tissue factor-initiated system, *Blood*, 86 (Suppl 1):77a.

Hoffman, M, DM Monroe, **JA Oliver**, and HR Roberts. 1995. Factor IXa and Xa play distinct roles in initiation of coagulation by tissue factor, *Thromb. Haemost.*, 73:1175.

Hudetz, AG, **JA Oliver**, JD Wood, PJ Newman, and JP Kampine. 1995. In vivo microscopy of leukocyte-endothelial interaction in cerebral ischemia reperfusion, *Anesthesiology*, 83 (Suppl 3A):A592.

**Oliver, JA** and RM Albrecht. 1989. Cytochalasin B enhances aggregation of gel-filtered human platelets: Relationship between platelet morphology and aggregability, *J. Cell Biol.*, 109:172a.

Orchekowski, RP, **JA Oliver**, RM Albrecht, and TJ Kunicki. 1988. Platelet-platelet cohesion: A novel mechanism that may be independent of glycoprotein IIb-IIIa, *J. Cell Biol.*, 107:383a.

**Oliver, JA**, R Piotrowicz, RP Orchekowski, TJ Kunicki, RM Albrecht. 1988. Adherence of platelets to fibronectin- and collagen coated-substrates, October, 1988 Conference on Platelet Structure, Platelet Membranes, and RGD Receptors, Madison, WI.

**Oliver, JA** and RM Albrecht. 1987. The role of pseudopodia in epinephrine- and ADP-induced-platelet aggregation, *Fed. Proc.*, 46:1315.

## Funding

### Current:

"Development of Platelet-Targeted Nanoparticles for Treatment of Thrombotic Stroke;" **Sole Principle Investigator**, Julie A. Oliver, UW-Milwaukee; Agency, American Heart Association; Type, Scientist Development Grant, National Center Research Program; Period, 01/01/2009 – 12/31/2012, request for fifth year, no-cost extension pending; Direct Costs, \$70,000 per year; Total Costs, \$308,000.

### Completed:

"Development of Platelet-Targeted Nanoparticles for Treatment of Thrombotic Stroke;" **Sole Principle Investigator**, Julie A. Oliver, UW-Milwaukee; Agency, UW-Milwaukee Graduate

School; Type, Research Growth Initiative; Period, 07/01/08 – 12/31/09; Total Costs, \$128,563.

“Synthesis and Atomic Characterization of Iron Oxide-Gold Core-Shell Nanoparticles, and Their Use in Cell-Targeted Therapies;” **Lead Principle Investigator**, Julie A. Oliver, UW-Milwaukee; Co-Investigators, Marija Gajardziska-Josifovska, UW-Milwaukee (Physics), Ralph M. Albrecht (Animal Sciences), UW-Madison, and Paul Voyles (Materials Science), UW-Madison; Agency, UWM Research Foundation; Program, Intercampus Research Incentive Grants Program; Period, 07/01/2010 – 10/31/2011; Total Costs \$50,000 (\$13,365 total to Oliver).

### **Invited Presentations**

Invited to speak at the 2<sup>nd</sup> Annual International Symposium of Hematology in Beijing, China, May 23-25, 2013. Unable to accept the invitation.

Invited to speak at the 1<sup>st</sup> Annual International Symposium of Hematology in Beijing, China, June 2012 (Track “Coagulation Biochemistry, Pathogenesis, and Disorders”). Declined.

October 2011, Research Colloquium Series, Department of Biological Sciences, University of Wisconsin-Milwaukee. Hosted by Steven Forst.

October 2011, Biophysics Seminar Series, Department of Physics, University of Wisconsin-Milwaukee. Hosted by Valerica Raicu.

March 2011, Research Service, Minneapolis VA Medical Center. Hosted by Ronald R. Bach; approved for continuing medical education (CME) credit.

March 2009, Cell & Molecular Biology Group, University of Wisconsin-Milwaukee

July 2008, Department of Dermatology, Kanazawa University, Kanazawa, Japan (presented in English)

September 2006, Research Colloquium Series, Department of Biological Sciences, University of Wisconsin-Milwaukee

May 2006, Department of Biology, University of Illinois-Springfield

March 2006, Department of Biological Sciences, St. Cloud State University, St. Cloud, MN

February 2006, Department of Chemistry & Physics, Milwaukee School of Engineering, Milwaukee, WI

October 2001, Biological Products Division, Bayer Corporation, Research Triangle Park, NC

May 2000, Company-wide Research Update, Pharmanetics, Inc., Raleigh, NC

July 1999, Research Division, Cardiovascular Diagnostics, Raleigh, NC

June 1999, Tissue Factor & Factor VIIa Research Group, Novo-Nordisk A/S, Måløv, Denmark (presented in English)

June 1999, Division of Clinical Chemistry, Lund University, Malmö, Sweden (presented in English). Hosted by Björn Dahlbäck.

January 1999, Center for Thrombosis and Hemostasis, University of North Carolina-Chapel Hill

August 1998, Tissue Factor & Factor VIIa Research Group, Novo-Nordisk, A/S, Gentofte, Denmark (presented in English). Hosted by Mirella Ezban.

August 1994, Department of Anesthesiology, Medical College of Wisconsin

July 1994, Center for Thrombosis and Hemostasis, University of North Carolina-Chapel Hill

July 1994, Department of Physiology, George Washington University School of Medicine, Washington, DC

March 1994, Amgen Corporation, presentation to visiting collaborators at the Blood Research Institute, The Blood Center of Southeastern Wisconsin

November 1993, Research Technologists' Continuing Education Program, The Blood Center of Southeastern Wisconsin

February 1992, Blood Research Institute, The Blood Center of Southeastern Wisconsin

March 1987, Hematology Research Group, Department of Medicine, University of Wisconsin-Madison

### **Memberships**

1982 – present	Member, American Association for the Advancement of Science
1995 – 1999	Associate Member, American Society of Hematology
1999 – present	Member, American Society of Hematology
2007 – present	Member, International Society on Thrombosis and Haemostasis
2010 – present	Member, Microscopy Society of America
2010 – present	Member, American Heart Association
2012 – present	Member, Midwest Microscopy and Microanalysis Society

### **Professional Service**

#### **Panel Participation:**

NSF-UWM Symposium, Open Forum for Innovation in Two-Photon Microspectroscopy, April 19 – 20, 2013, Milwaukee, WI; "Session IV," **Chair**.

#### **Reviewing:**

Microscopy Society of America Undergraduate Research Scholarships, 2009  
Journal of Clinical Investigation – ad hoc  
Journal of Biological Chemistry – ad hoc  
Colloids and Surfaces B: Biointerfaces – ad hoc  
Biomedical Materials – ad hoc  
Scanning – ad hoc  
Microscopy and Microanalysis – ad hoc  
Nanotechnology – ad hoc  
Medical Hypotheses – ad hoc  
Histochemistry and Cell Biology – ad hoc

#### **Departmental:**

Biological Sciences Awards and Publicity Committee, 2006-2007  
Biological Sciences Course and Curriculum Committee, 2007-present; **Co-Chair**, 2008-2010  
Biological Sciences Committee to Reorganize BioSci 316 (**Chair**), 2007-2009  
Biological Sciences Search Committee, Cell and Molecular Biology faculty search, 2008-2009  
Poster judging for 2009 Biological Sciences Research Symposium

#### **Campus-Wide:**

New Directions Scholarship Committee, 2013-2014  
UW-Milwaukee Institutional Biosafety Committee, 2012-present  
UW-Milwaukee Animal Resource and Policy Committee, 2006-present  
UW-Milwaukee Open House, Biological Sciences booth, October 2007, 2008, 2010, and 2012

### **Direct Research Supervision**

#### **Graduate Students:**

Vyacheslav Strogolov, MS student, September 2007 – December 2010 (degree granted)  
Evan S. Krystofiak, PhD student, September 2007 – August 2013 (degree granted)  
Winner Microscopy Society of America Presidential Student Award, 2012  
Winner Midwest Microscopy and Microanalysis Society Student Travel Award, 2012 (declined)  
Winner Ruth Walker Graduate Grant-in-Aid, 2008, 2009, 2011, 2012  
Winner Joseph B. Baier Award 2008, 2010  
Winner Best Graduate Poster, UW-Milwaukee Biological Sciences Research Symposium, 2009

#### **Undergraduate Students:**

James Dean, June 2009 – May 2011  
Recipient of competitive Undergraduate Research Internship, Spring 2010  
Recipient of SURF Award for S&E, academic year 2010 – 2011  
Winner of Ruth Walker Graduating Senior Award, May 2011  
Ulrike Galasinski, September 2010 – May 2011  
Recipient of SURF Award for S&E, academic year 2010 – 2011  
Winner of Ruth Walker Undergraduate Grant-in-Aid, academic year 2010 – 2011  
Briccio Guillermo, January 2010 – May 2010  
Brian Buss, January 2009 – May 2010  
Janel Cornellier, January 2010 – May 2010  
Megan Schultz, September 2008 – May 2009  
Ashley Luka, September 2007 – May 2009  
Recipient of competitive Enhanced Research Opportunity stipend, Spring, 2009  
Vyacheslav Strogolov, September 2006 – May 2007

#### **Technical Staff:**

Linda G. Westrick, MT (ASCP), MS, July 2008 – June 2012  
Juleen M. Dickson, MS, June 2012 – August 2013

#### **Visiting Scientists / Postdoctoral Fellows:**

Yasser Abdel Galil Ahmed, PhD, Visiting Scientist, October 2012 – October 2013

### **Thesis Committees and Academic Advising**

19 graduate thesis committees to date (includes 2 students from my laboratory)  
40 Biological Sciences undergraduate academic advisees to date

### **Summary of Teaching Experience (detailed list available upon request)**

#### **Professor / Instructor, UW-Milwaukee:**

Immunology Lecture (undergraduate/graduate), one semester  
Immunology Laboratory (undergraduate/graduate), four semesters  
Laboratory in Genetics and Cell Biology (undergraduate), seven semesters, scheduled for Fall 2013  
Senior Seminar (undergraduate), one semester

Cell and Molecular Biology Seminar (graduate), three semesters  
Cell Biology Lecture (undergraduate), planned for spring 2014

**Teaching Assistant, UW-Madison School of Pharmacy:**

Pharmaceutical Biochemistry, one semester  
Biopharmaceutics, one semester  
Survey of Pharmacology, one semester

**Undergraduate Tutor, Academic Skills Center, UW-Eau Claire:**

Biology, Chemistry, and Biochemistry, one academic year

**Patents**

Duke Technology Numbers 1259, 1841, 2087, 2238, 2369, and 2558. These file numbers are covered under a licensing agreement between Collective Therapeutics and Duke University + Dana-Farber Cancer Institute, and include CD19 applications, CD20 applications, CD22 applications, and MS4A applications. The rights of nine patent application numbers and the associated biological materials are included in the agreement. My role, which was the development and characterization of biological materials used in the testing of therapeutic monoclonal antibodies, led to 2% of the proceeds covered by the license.

**Consulting**

August, 1998, in Gentofte, Denmark. Collaborated with the Tissue Factor / Factor VIIa Division of Novo Nordisk A/S, on the development of a cell-based coagulation assay. With Drs. Marianne Kjalke and Mirella Ezban.

May – June, 1999, in Måløv, Denmark. Paid consultant for the Tissue Factor / Factor VIIa Division of Novo Nordisk A/S, on the development of a cell proliferation assay for testing the effects of NovoSeven (activated factor VII). Supervised by Dr. Mirella Ezban.

**Referees**

Available upon request